JP2024543125A5 - - Google Patents

Info

Publication number
JP2024543125A5
JP2024543125A5 JP2024530529A JP2024530529A JP2024543125A5 JP 2024543125 A5 JP2024543125 A5 JP 2024543125A5 JP 2024530529 A JP2024530529 A JP 2024530529A JP 2024530529 A JP2024530529 A JP 2024530529A JP 2024543125 A5 JP2024543125 A5 JP 2024543125A5
Authority
JP
Japan
Application number
JP2024530529A
Other languages
Japanese (ja)
Other versions
JPWO2023094818A5 (https=
JP2024543125A (ja
Filing date
Publication date
Priority claimed from GBGB2117005.5A external-priority patent/GB202117005D0/en
Priority claimed from GBGB2208144.2A external-priority patent/GB202208144D0/en
Priority claimed from GBGB2213306.0A external-priority patent/GB202213306D0/en
Application filed filed Critical
Priority claimed from PCT/GB2022/052985 external-priority patent/WO2023094818A1/en
Publication of JP2024543125A publication Critical patent/JP2024543125A/ja
Publication of JPWO2023094818A5 publication Critical patent/JPWO2023094818A5/ja
Publication of JP2024543125A5 publication Critical patent/JP2024543125A5/ja
Pending legal-status Critical Current

Links

JP2024530529A 2021-11-25 2022-11-25 バイオ医薬品化合物を含む医薬組成物 Pending JP2024543125A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2117005.5A GB202117005D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition
GB2117005.5 2021-11-25
GB2208144.2 2022-06-01
GBGB2208144.2A GB202208144D0 (en) 2022-06-01 2022-06-01 New pharmaceutical composition
GB2213306.0 2022-09-12
GBGB2213306.0A GB202213306D0 (en) 2022-09-12 2022-09-12 New pharmaceutical composition
PCT/GB2022/052985 WO2023094818A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising biopharmaceutical drug compounds

Publications (3)

Publication Number Publication Date
JP2024543125A JP2024543125A (ja) 2024-11-19
JPWO2023094818A5 JPWO2023094818A5 (https=) 2025-12-02
JP2024543125A5 true JP2024543125A5 (https=) 2025-12-02

Family

ID=84367624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530529A Pending JP2024543125A (ja) 2021-11-25 2022-11-25 バイオ医薬品化合物を含む医薬組成物

Country Status (11)

Country Link
US (1) US20240408212A1 (https=)
EP (1) EP4436551A1 (https=)
JP (1) JP2024543125A (https=)
KR (1) KR20240111761A (https=)
AR (1) AR127783A1 (https=)
AU (1) AU2022398370A1 (https=)
CA (1) CA3239053A1 (https=)
IL (1) IL313015A (https=)
MX (1) MX2024006130A (https=)
TW (1) TW202329916A (https=)
WO (1) WO2023094818A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
DE69913113T2 (de) 1998-03-10 2004-08-26 Valois S.A.S. Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
AU2003272959A1 (en) 2003-10-09 2005-04-27 Bioactis Limited Powdery medicine dispensing device for nasal cavity
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5623355B2 (ja) 2010-07-30 2014-11-12 オートリブ ディベロップメント エービー カーテンエアバッグ
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
RU2720808C2 (ru) * 2013-09-03 2020-05-13 Джорджия Тек Рисёч Корпорейшн Термостабильные препараты вакцин и микроиглы
CN104489669A (zh) * 2014-12-12 2015-04-08 深圳先进技术研究院 一种植物酵素益生菌粉及其制备方法
US11331270B2 (en) 2017-08-20 2022-05-17 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
EP3698773A1 (en) * 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098420B1 (fr) 2019-07-10 2021-07-09 Aptar France Sas Dispositif de distribution nasale de poudre
RS63725B1 (sr) * 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre

Similar Documents

Publication Publication Date Title
CL2025003833A1 (es) Control mejorado de redes eléctricas
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13135U (https=)